Clearance of the Micro-Coring technology provides a new anti-aging aesthetic skin treatment category, designed to provide a faster healing time without burns or scarring.

Cytrellis recently announced that the U.S. Food and Drug Administration (FDA) has cleared its first proprietary product, the Ellacor system with Micro-Coring technology, for the treatment of moderate to severe wrinkles in the mid to lower face. This minimally-invasive, first-in-category device is designed to safely and effectively remove micro-sized portions of excess skin without surgery, thermal energy or evidence of scarring.

“We are thrilled to receive this FDA clearance for our Micro-Coring technology. It is a result of our team’s extensive research and collaboration with leading physicians in the aesthetics industry. We have developed a truly innovative device,” shared Karen Cronholm, president and chief executive officer of Cytrellis. “Ellacor is a simple, yet more effective procedure that provides patients and physicians with what they have been asking for — natural looking results.”

Based on the initial research of its scientific founders, William Austen Jr., MD, and Rox Anderson, FAAD, Cytrellis was able to introduce this technology — a novel system made to mechanically remove full-thickness cores of skin. “It can remove as much skin as some surgical procedures without scarring,” said William G. Austen, Jr. MD, chief of plastic and reconstructive surgery, chief of burn surgery at Massachusetts General Hospital (MGH) in Boston, Mass, and professor of surgery at Harvard Medical School.

Rox Anderson, MD, director of the Wellman Center for Photomedicine at MGH and Harvard Medical School professor of dermatology, commented: “Cytrellis has created a new treatment option for aging skin. For some patients, we can use this technology instead of lasers or conventional surgery, allowing for faster healing time without burns or scarring.”